SCHEMBL23630488

SCHEMBL23630488

COC(=O)c1ccnc(N2CCN(C(=O)O)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.58
KDM4E B2RXH2 5/20 0.54
KDM4C Q9H3R0 2/20 0.54
KDM6B O15054 1/20 0.54
KDM5C P41229 1/20 0.54
KDM2A Q9Y2K7 1/20 0.54
KDM3A Q9Y4C1 1/20 0.54
PIK3CA P42336 2/20 0.52
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
POLB P06746 1/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
JMJD6 Q6NYC1 1/20 0.48
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
KDM5A P29375 2/20 0.46
KDM5B Q9UGL1 2/20 0.46
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750019 0.85 HRH3 (0.57) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL20938625 0.84 HRH3 (0.59) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL5929302 0.83 PIK3CA (0.54) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL2028882 0.83 PIK3CA (0.57) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL1021177 0.82 HRH3 (0.54) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL17843238 0.82 HRH3 (0.54) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL31704530 0.82 PIK3CA (0.74) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL1516978 0.82 PIK3CA (0.74) HRH3KDM4EKDM4CKDM6BKDM5C
Hydrochloric Acid SCHEMBL23630502 0.81 HRH3 (0.53) HRH3KDM4EKDM4CKDM6BKDM5C
SCHEMBL390338 0.81 HRH3 (0.56) HRH3KDM4EKDM4CKDM6BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230091042-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2023-03-23 US disclosed
WO-2021142247-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2021-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230091042-A1 SMARCA2-VHL DEGRADERS VHL, SMARCC2, SMARCC1 HRH3 2879/4885KDM4E 178/4885KDM4C 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.